BioSpace News Archive

Takeda Pharmaceutical Company Limited announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG for a total value of $660 million USD.

An emergency ambulance is a vehicle useful in emergency cases such as road accidents, and heart attacks and cardiac arrest cases.

The HIV Care ValueSM program, part of the company’s SafeGuardRx® platform, will drive value and improve cost predictability for employers, health plans, and people at risk for HIV

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, today announced the publication of research on the discovery of a novel class of candidate antimalarial agents that block multiple stages of the lifecycle of the parasite that causes the disease.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s fourth quarter 2019 financial results will be released on Wednesday, March 11, 2020

In the fight against the Corona virus, Bactiguard donates products for infection prevention to Chinese hospitals, at a market value of over 2 million SEK .

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable, sample-to-answer molecular testing platform designed for point-of-care (POC) infectious disease diagnosis, today announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza clinical trial in China.

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced proof of concept data for a next generation dual conjugated combination

Allurion Technologies, an established leader in the development of innovative, proven, and trusted weight loss experiences, today—on World Obesity Day—announced its commitment to treat 40,000 individuals around the world and shed over one million pounds by the end of 2020.